Interpace Diagnostics Group (NASDAQ:IDXG) & Globus Medical (NASDAQ:GMED) Critical Comparison
Interpace Diagnostics Group (NASDAQ:IDXG) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Volatility and Risk
Interpace Diagnostics Group has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
This table compares Interpace Diagnostics Group and Globus Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-53.75%||-34.69%||-24.37%|
This is a summary of current recommendations and price targets for Interpace Diagnostics Group and Globus Medical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||3||0||3.00|
Interpace Diagnostics Group currently has a consensus price target of $4.00, indicating a potential upside of 393.83%. Globus Medical has a consensus price target of $54.89, indicating a potential upside of 31.94%. Given Interpace Diagnostics Group’s stronger consensus rating and higher probable upside, research analysts clearly believe Interpace Diagnostics Group is more favorable than Globus Medical.
Insider and Institutional Ownership
22.8% of Interpace Diagnostics Group shares are owned by institutional investors. Comparatively, 66.5% of Globus Medical shares are owned by institutional investors. 2.8% of Interpace Diagnostics Group shares are owned by company insiders. Comparatively, 25.0% of Globus Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Interpace Diagnostics Group and Globus Medical’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Interpace Diagnostics Group||$21.90 million||1.41||-$12.19 million||($0.43)||-1.88|
|Globus Medical||$712.97 million||5.78||$156.47 million||$1.67||24.91|
Globus Medical has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Globus Medical beats Interpace Diagnostics Group on 11 of the 14 factors compared between the two stocks.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Globus Medical Company Profile
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.